Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Vivus Inc VVUSQ

Healthcare Biotechnology
VIVUS Inc is a US-based biopharmaceutical company engaged in developing and commercializing, next-generation therapies to address unmet medical needs in human health. Its commercial products include Qsymia, an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index; PANCREAZE which is a is a pancreatic... see more

Recent & Breaking News (OTCPK:VVUSQ)

VIVUS Announces Acquisition of Topiramate-Related Patents From Janssen Pharmaceuticals

Marketwired August 25, 2014

VIVUS Reports Second Quarter 2014 Financial Results

Marketwired August 7, 2014

VIVUS Announces Date of Second Quarter 2014 Update and Financial Results Conference Call

GlobeNewswire July 31, 2014

VIVUS Files Lawsuit Against Actavis for Infringement of Qsymia Patents

Marketwired June 12, 2014

VIVUS to Present at Upcoming Investor Conference

Marketwired June 12, 2014

Orexigen (OREX) Tumbling on FDA Delay for New Obesity Drug

Equities.com June 11, 2014

Avanafil Clinical Data to Be Presented at American Urological Association

Marketwired May 19, 2014

VIVUS Announces Qsymia Presentation at the American Association of Clinical Endocrinologists (AACE)

Marketwired May 15, 2014

VIVUS to Present at Upcoming Investor Conference

Marketwired May 8, 2014

VIVUS Reports First Quarter 2014 Financial Results

Marketwired May 5, 2014

VIVUS Reports First Quarter 2014 Financial Results

Marketwired May 5, 2014

VIVUS Announces Date of First Quarter 2014 Update and Financial Results Conference Call

GlobeNewswire April 29, 2014

Avanafil Clinical Data to Be Presented at European Association of Urology

Marketwired April 11, 2014

Avanafil Clinical Data to Be Presented at European Association of Urology

Marketwired April 11, 2014

Three VIVUS Directors Not Standing for Re-Election

Marketwired April 8, 2014

Three VIVUS Directors Not Standing for Re-Election

Marketwired April 8, 2014

VIVUS to Present at Upcoming Investor Conference

Marketwired April 3, 2014

VIVUS to Present at Upcoming Investor Conference

Marketwired April 3, 2014

Newly Published Review Article Summarizes Cardiovascular Benefit-Risk Profile of Qsymia

Marketwired March 25, 2014

Newly Published Review Article Summarizes Cardiovascular Benefit-Risk Profile of Qsymia

Marketwired March 25, 2014